CSF proteomic analysis in patients with normal pressure hydrocephalus selected for the shunt: CSF biomarkers of response to surgical treatment

Neurological Sciences

Volumn 31, Issue 3, 2010, Pages 283-291

  Scollato, Antonio ^a   Terreni, Alessandro ^b   Caldini, Anna ^b   Salvadori, Benedetta ^b   Gallina, Pasquale ^a   Francese, Simona ^a   Mastrobuoni, Guido ^a   Pieraccini, Giuseppe ^a   Moneti, Gloriano ^a   Bini, Luca ^c   Messeri, Gianni ^b   Di Lorenzo, Nicola ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

Author keywords

2D electrophoresis; Cerebrospinal fluid; Normal pressure hydrocephalus; Proteoma

Indexed keywords

ALBUMIN; ALPHA 1 ANTICHYMOTRYPSIN; ALPHA 2 ANTIPLASMIN; ALPHA1 GLYCOPROTEIN; ANTITHROMBIN; APOLIPOPROTEIN E; BIOLOGICAL MARKER; CLUSTERIN; COMPLEMENT COMPONENT C3C; FETUIN A; GLIAL FIBRILLARY ACIDIC PROTEIN; PROTEOME;

AGED; ARTICLE; BRAIN VENTRICLE PERITONEUM SHUNT; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; HUMAN; INTRACRANIAL PRESSURE MONITORING; MALE; MASS SPECTROMETRY; NORMOTENSIVE HYDROCEPHALUS; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PATHOGENESIS; PATIENT SELECTION; PILOT STUDY; PREDICTION; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID SHUNTING; FOLLOW UP; INTRACRANIAL PRESSURE; PEPTIDE MAPPING; TIME; TREATMENT OUTCOME;

AGED; BIOLOGICAL MARKERS; CEREBROSPINAL FLUID SHUNTS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROCEPHALUS, NORMAL PRESSURE; INTRACRANIAL PRESSURE; MALE; PATIENT SELECTION; PEPTIDE MAPPING; PILOT PROJECTS; PROTEOME; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TIME FACTORS; TREATMENT OUTCOME;

EID: 77955872780     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-009-0181-0     Document Type: Article

References (51)

1. adams RD, Fischer CM, Hakim S, Ojemann RG, Sweet WH (1965) Symptomatic occult hydrocephalus with "normal" cerebrospinal fluid pressure: a treatable syndrome. N Engl J Med 273:117-126
2. Fisher CM (1982) Hydrocephalus as a cause of disturbances of gait in the elderly. Neurology 32:1358-1363
3. Black P (1980) Idiopathic normal-pressure hydrocephalus. Results of shunting in 62 patients. J Neurosurg 52:371-377
4. Bergsneider M, Black PM, Klinge P, Marmarou a, Relkin N (2005) Surgical management of idiopathic normal-pressure hydrocephalus. Neurosurgery 57(3 Suppl):S29-S39
5. Savolainen S, Paljarvi L, Vapalahti M (1999) Prevalence of alzheimer's disease in patients investigated for presumed normal pressure hydrocephalus: a clinical and neuropathological study. acta Neurochir (Wien) 141:849-853
6. Vanneste J, augustijn P, Dirven C, Tan WF, Goedhart ZD (1992) Shunting normal-pressure hydrocephalus: do the benefits outweigh the risks? a multicenter study and literature review. Neurology 42:54-59
7. Vanneste J, augustijn P, Davies Ga, Dirvan C, Tan WF (1992) Normal-pressure hydrocephalus: is cisternography still useful in selecting patients for a shunt? arch Neurol 49:366-370
8. Malm J, Kristensen B, Karlsson T, Fagerlund M, Elfverson J, Ekstedt J (1995) The predictive value of cerebrospinal fluid dynamic tests in patients with the idiopathic adult hydrocephalus syndrome. arch Neurol 52:783-789
9. Walchenbach R, Geiger E, Thomeer RT, Vanneste Ja (2002) The value of temporary external lumbar CSF drainage in predicting the outcome of shunting on normal pressure hydrocephalus. J Neurol Neurosurg Psychiatry 72:503-506
10. Boon aJ, Tans JT, Delwel EJ, Egeler-Peerdeman SM, Hanlo PW, Wurzer Ha et al (1997) Dutch normal-pressure hydrocephalus study: prediction of outcome after shunting by resistance to outflow of cerebrospinal fluid. J Neurosurg 87:687-693
11. Raftopoulos C, Chaskis C, Delecluse F, Cantraine F, Bidaut L, Brotchi J (1992) Morphological quantitative analysis of intracranial pressure waves in normal pressure hydrocephalus. Neurol Res 14:389-396
12. Williams Ma, Razumovsky aY, Hanley DF (1998) Comparison of Pcsf monitoring and controlled CSF drainage diagnose normal pressure hydrocephalus. acta Neurochir Suppl 71:328-330
13. Brettschneider J, Riepe MW, Petereit HF, Ludolph aC, Tumani H (2004) Meningeal derived cerebrospinal fluid proteins in different forms of dementia: is a meningopathy involved in normal pressure hydrocephalus? J Neurol Neurosurg Psychiatry 75:1614-1616
14. Nacmias B, Tedde a, Guarnieri BM, Petruzzi C, Ortenzi L, Serio a et al (1997) analysis of apolipoprotein E, alpha1-antichymotripsin and presenilin-1 genes polymorphisms in dementia caused by normal pressure hydrocephalus in man. Neurosci Lett 229:177-180
15. Choe LH, Dutt MJ, Relkin N, Lee KH (2002) Studies of potential cerebrospinal fluid molecular markers for alzheimer's disease. Electrophoresis 23:2247-2251
16. Silverberg GD, Mayo M, Saul T, Rubenstein E, McGuire D (2003) alzheimer's disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis. Lancet Neurol 2:506-511
17. Silverberg GD, Heit G, Huhn S, Jaffe Ra, Chang SD, Bronte- Stewart H et al (2001) The cerebrospinal fluid production rate is reduced in dementia of the alzheimer's type. Neurology 57:1763-1766
18. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". a practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res 12:189-198
19. Raftopoulos C, Deleval J, Chaskis C, Leonard a, Cantraine F, Desmyttere F, Clarysse S, Brotchi J (1994) Cognitive recovery in idiopathic normal pressure hydrocephalus: a prospective study. Neurosurgery 35(3):397-404
20. Castagna a, Campostrini N, Farinazzo a, Zanusso G, Monaco S, Righetti PG (2002) Comparative two-dimensional mapping of prion protein isoforms in human cerebrospinal fluid and central nervous system. Electrophoresis 23:339-346
21. Prosinecki V, Botelho HM, Francese S, Mastrobuoni G, Moneti G, Urich M, Kletzin a, Gomes CM (2006) a proteomic approach toward the selection of proteins with enhanced intrinsic conformational stability. J Proteome Res 5:2720-2726
22. Nishihara JC, Champion KM (2002) Quantitative evaluation of proteins in one- and two-dimensional polyacrylamide gels using a fluorescent stain. Electrophoresis 23:2203-2215
23. Davson HK, Welch K, Segal MB (1987) The physiology and pathophysiology of the cerebrospinal fluid. Churchill Livingstone, New York
24. May C, Kaye Ja, atack JR, Schapiro MB, Friedland RP, Rapoport SI (1990) Cerebrospinal fluid production is reduced in healthy aging. Neurology 40:500-503
25. Knuckey NW, Preston J, Palm D, Epstein MH, Johanson C (1993) Hydrocephalus decreases chloride efflux from the choroids plexus epithelium. Brain Res 618:313-317
26. Preston JE (2001) ageing choroid plexus-cerebrospinal fluid system. Microsc Res Tech 52:31-37
27. Johanson C, McMillan P, Tavares R, Spangenberger a, Duncan J, Silverberg G et al (2004) Homeostatic capabilities of the choroid plexus epithelium in alzheimer's disease. Cerebrospinal Fluid Res 1:3
28. Veenstra TD, Conrads TP, Hood BL, avellino aM, Ellenbogen RG, Morrison RS (2005) Biomarkers: mining the biofluid proteome. Mol Cell Proteomics 4:409-418
29. Petzold a, Keir G, Green aJ, Giovannoni G, Thompson EJ (2004) an ELISa for glial fibrillary acidic protein. J Immunol Methods 287:169-177
30. Greber S, Lubec G, Cairns N, Fountoulakis M (1999) Decreased levels of synaptosomal associated protein 25 in the brain of patients with Down syndrome and alzheimer's disease. Electrophoresis 20(4-5):928-934 (Pubitemid 29222451)
31. Boyles JK, Notterpek LM, anderson LJ (1990) accumulation of apolipoproteins in the regenerating and remyelinating mammalian peripheral nerve. J Biol Chem 265:17805-17815
32. Puchades M, Hansson SF, Nilsson CL, andreasen N, Blennow K, Davidsson P (2003) Proteomic studies of potential cerebrospinal fluid protein markers for alzheimer's disease. Mol Brain Res 118:140-146 (Pubitemid 37238996)
33. Ishioka N, Takahashi N, Putnam FW (1986) amino acid sequence of human plasma a1B-glycoprotein: homology to the immunoglobulin supergene family. Proc Natl acad Sci USa 83:2363-2367
34. Lescuyer P, Hochstrasser DF, Sanchez JC (2004) Comprehensive proteome analysis by chromatographic protein prefractionation. Electrophoresis 25:1125-1135
35. Holtzmann DM (2004) In vivo effects of apoE and clusterin on amyloid-beta metabolism and neuropathology. J Mol Neurosci 23:247-254
36. Jenne DE, Lowin B, Peitsch MC, Böttcher a, Schmitz G, Tschopp J (1991) Clusterin (complement lysis inhibitor) forms a high density lipoprotein complex with apolipoprotein a-I in human plasma. J Biol Chem 266:11030-11036
37. May PC, Lampert-Etchells M, Johnson Sa, Poirier J, Masters JN, Finch CE (1990) Dynamics of gene expression for a hippocampal glycoprotein elevated in alzheimer's disease and in response to experimental lesions in rat. Neuron 5:831-839
38. Ghiso J, Matsubara E, Koudinov a, Choi-Miura NH, Tomita M, Wisniewski T et al (1993) The cerebrospinal-fluid soluble form of alzheimer's amyloid beta is complexed to SP-40, 40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem J 293:27-30
39. Munoz DG, Erkinjuntti T, Gaytan-Garcia S, Hachinski V (1997) Serum protein leakage in alzheimer's disease revisited. ann N Y acad Sci 826:173-189
40. Takeuchi T, Kasahara E, Iwasaki M, Mima T, Mori K (2000) Indications for shunting in patients with idiopathic normal pressure hydrocephalus presenting with dementia and brain atrophy (atypical idiopathic normal pressure hydrocephalus). Neurol Med Chir (Tokyo) 40:38-46
41. abraham CR, Selkoe DJ, Potter H (1988) Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of alzheimer's disease. Cell 52:487-501
42. Gingrich MB, Traynelis SF (2000) Serine proteases and brain damage-is there a link? Trends Neurosci 23:399-407
43. Li X, Miyajima M, Mineki R, Taka H, Murayama K, arai H (2006) analysis of potential diagnostic biomarkers in cerebrospinal fluid of idiopathic normal pressure hydrocephalus by proteomics. acta Neurochir (Wien) 148(8):859-864
44. Geroldi D, Minoretti P, Bianchi M, Di Vito C, Reino M, Bertona M et al (2005) Genetic association of alpha2-Heremans-Schmid glycoprotein polymorphism with late-onset alzheimer's disease in Italians. Neurosci Lett 386:176-178
45. Nawratil P, Lenzen S, Kellermann J, Haupt H, Schinke T, Muller- Esterl W et al (1996) Limited proteolysis of human alpha2-HS glycoprotein/fetuin. Evidence that a chymotryptic activity can release the connecting peptide. J Biol Chem 271:31735-31741
46. Masliah E, Ho G, Wyss-Coray T (2001) Functional role of TGF beta in alzheimer's disease microvascular injury: lessons from transgenic mice. Neurochem Int 39:393-400
47. Calero M, Rostagno a, Frangione B, Ghiso J (2005) Clusterin and alzheimer's disease. Subcell Biochem 38:273-298
48. Mhatre M, Nguyen a, Kashani S, Pham T, adesina a, Grammas P (2004) Thrombin, a mediator of neurotoxicity and memory impairment. Neurobiol aging 25:783-793
49. Brettschneider J, Claus a, Kassubek J, Tumani H (2005) Isolated blood-cerebrospinal fluid barrier dysfunction: prevalence and associated diseases. J Neurol 252:1067-1073
50. Garcia JH, Ho KL, Caccamo DV (1994) Intracerebral hemorrhage: pathology of selected topics. In: Kase CS, Caplan LR (eds) Intracerebral hemorrhage. Butterworth-Heinemann, Boston, pp 45-72
51. Silverberg GD, Levinthal E, Sullivan EV, Bloch Da, Chang SD, Leverenz J et al (2002) assessment of low-flow CSF drainage as a treatment for aD: results of a randomized pilot study. Neurology 59:1139-1145